Related Experiment Video
Updated: Sep 15, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Neuroimmunology-driven CAR T-cell therapeutics for gliomas: translational challenges and clinical trial paradigm
Zhipeng Li1, Fan Yang2, Siyuan Lu1
1Department of Neurosurgery, First Affiliated Hospital of China Medical University, Shenyang, China.
Abstract:
Glioma, a category of the most lethal primary brain tumors, remains incurable despite multimodal therapy combining maximal resection, radiation, and temozolomide. These interventions invariably fail due to residual invasive cells, molecular heterogeneity, and an immunosuppressive tumor microenvironment (TME) reinforced by myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). The blood-brain barrier (BBB) further limits therapeutic access, while antigen escape and T-cell exclusion mechanisms drive relapse. Chimeric antigen receptor (CAR) T-cell therapy, transformative in relapsed B-cell malignancies with sustained remission rates, faces formidable yet surmountable barriers in solid tumors. Recent advances in CAR-T trials targeting glioma-associated antigens demonstrate partial intracranial activity, albeit with transient efficacy, underscoring the need for neuroimmunology-informed engineering. This review critically evaluates CAR-T strategies countering glioma-specific resistance: bispecific antigen targeting combats tumor plasticity, cytokine-armored designs neutralize immunosuppression, and innovative delivery routes enhance CNS bioavailability. Early clinical outcomes reveal critical divergence points from hematologic success, including antigen loss due to glioma's evolutionary capacity and T-cell exhaustion within hypoxic niches. Emerging solutions integrate CRISPR-edited allogeneic platforms with combinatorial immunomodulation (e.g., myeloid-targeting) and delivery innovations to address these barriers. We further dissect translational priorities including neurotoxicity mitigation and scalable manufacturing for infiltrative glioma phenotypes. By converging advances in immune-engineering, TME remodeling, and biomarker-driven trial designs, this work proposes a roadmap to achieve durable CAR-T efficacy in GBM. The synthesis bridges mechanistic insights into glioma-immune interactions with clinical translation strategies, aiming to transcend current limitations of transient cytoreduction and establish CAR-T therapy as a cornerstone of neuro-oncologic practice.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for brain tumors like glioma, but faces challenges. Engineering CAR-T cells to overcome tumor resistance and immunosuppression is key for durable efficacy.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Biology
Background:
- Glioma is a lethal brain tumor resistant to current multimodal therapies.
- Tumor microenvironment (TME), blood-brain barrier (BBB), and immune evasion limit treatment efficacy.
- Chimeric antigen receptor (CAR) T-cell therapy offers potential but faces significant hurdles in solid tumors.
Purpose of the Study:
- To critically evaluate CAR T-cell strategies for overcoming glioma-specific resistance mechanisms.
- To explore innovative approaches for enhancing CAR T-cell efficacy and overcoming treatment barriers in brain tumors.
- To propose a roadmap for achieving durable CAR T-cell efficacy in glioblastoma (GBM).
Main Methods:
- Review of current CAR T-cell strategies targeting glioma-associated antigens.
- Analysis of challenges including tumor plasticity, immunosuppression, BBB penetration, and T-cell exhaustion.
- Evaluation of emerging solutions like bispecific antigen targeting, cytokine-armored CAR-T cells, and novel delivery routes.
- Discussion of CRISPR-edited allogeneic platforms and combinatorial immunomodulation.
Main Results:
- CAR T-cell therapy has shown partial intracranial activity in glioma trials, but efficacy is often transient.
- Glioblastoma (GBM) presents unique resistance mechanisms such as antigen loss and T-cell exhaustion.
- Engineering strategies are being developed to counteract immunosuppression and improve T-cell function within the TME.
Conclusions:
- Overcoming glioma-specific resistance requires advanced CAR T-cell engineering, including bispecific targeting and cytokine-armored designs.
- Innovative delivery methods and combinatorial approaches (e.g., myeloid targeting) are essential for CNS bioavailability and efficacy.
- Addressing neurotoxicity and developing scalable manufacturing are critical translational priorities for successful CAR T-cell therapy in GBM.
More Related Videos
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
